469P - Metastasic breast cancer: Differences in motor activity and sleep patterns by kind of treatment

Background

Improving the quality of life, in addition to survival, is one of the main objectives of treating metastatic breast cancer. Among the primary treatments for most of these patients are hormonal therapies + CDK inhibitors or chemotherapy, which have varying toxicity profiles and impacts on quality of life. Hormonal therapies have been associated with improvements in quality of life based on questionnaires, but we have limited objective parameters to assess quality of life.

Methods

We analysed circadian rhythms in 55 metastasic breast cancer patients who were compared to healthy controls (digital twin) matched by age, weight, and height. The healthy controls were recruited from the Kronohealth database, which includes more than 10,000 subjects. The patients were divided in two groups by kind of treatment. Group 1 patients with first or second chemotherapy line and Group 2 patients with cyclin dependant kinasa inhibitor plus hormonal therapy All participants had Performance status 0 or 1. EUROQOL-5D 5L quality of life test was performed.

Results

The EQ-5D-5L scale did not show significant differences in any of the five aspects analyzed: pain, anxiety, mobility, usual activities, and self-care were evaluated as either without problems or with mild problems regardless of the treatments received. However, patients in group 1 exhibited patterns of aged rhythms compared to healthy controls, with decreased time and amplitude of movements (motor activity) and increased hours of sleep. Patients in group 2 maintained levels of physical activity similar to those of the control group, and there were no differences in sleep patterns. Body temperature was decreased in both groups of patients, and the recovery of temperature after the initiation of activity was slowed down compared to controls.

Conclusions

CDK Inhibitors plus hormonotherapy have a lesser impact on the quality of life compared to chemotherapy treatments in patients with metastatic breast cancer, as these patients maintain better levels of physical activity and less disrupted sleep patterns. We have observed a significant decrease in body temperature in oncology patients, which will be the subject of future investigations.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160”.

Disclosure

All authors have declared no conflicts of interest.